About Tiburio therapeutics
Tiburio Therapeutics: Revolutionizing the Treatment of Rare Diseases
Tiburio Therapeutics is a biopharmaceutical company that is dedicated to developing innovative treatments for rare and serious diseases. The company was founded in 2017 by a team of experienced scientists and entrepreneurs who recognized the need for new therapies that could address unmet medical needs.
The mission of Tiburio Therapeutics is to improve the lives of patients with rare diseases by developing novel treatments that target the underlying causes of their conditions. The company's approach is based on cutting-edge research in genetics, molecular biology, and drug discovery, which has led to the identification of promising drug candidates that have shown efficacy in preclinical studies.
One of Tiburio's key areas of focus is on disorders caused by mutations in genes that regulate intracellular trafficking. These disorders are characterized by defects in the transport and sorting of proteins within cells, which can lead to a wide range of symptoms depending on the affected organ system. Examples include lysosomal storage disorders, neurodegenerative diseases, and certain types of cancer.
Tiburio's lead drug candidate is TBR-760, a small molecule inhibitor that targets a protein called RAB35. RAB35 plays a critical role in regulating endosomal trafficking pathways, which are essential for maintaining cellular homeostasis. By inhibiting RAB35 activity, TBR-760 has been shown to correct trafficking defects associated with several rare diseases.
In preclinical studies using animal models and patient-derived cells, TBR-760 has demonstrated significant therapeutic potential for several lysosomal storage disorders such as Niemann-Pick disease type C (NPC) and mucolipidosis type IV (MLIV). These conditions are caused by mutations in genes involved in cholesterol metabolism or lysosomal function respectively leading to accumulation toxic substances inside cells resulting into severe neurological symptoms or multi-systemic dysfunction.
Tiburio also has ongoing research programs focused on other rare diseases, including certain types of cancer and neurodegenerative disorders. The company's approach is based on a deep understanding of the underlying biology of these conditions, which allows for the development of targeted therapies that can address specific disease mechanisms.
In addition to its drug discovery efforts, Tiburio Therapeutics is also committed to advancing the field of rare disease research through collaborations with academic institutions and patient advocacy groups. The company has established partnerships with leading experts in genetics and molecular biology, as well as with organizations that represent patients and families affected by rare diseases.
Overall, Tiburio Therapeutics represents a promising new player in the biopharmaceutical industry that is focused on developing innovative treatments for rare diseases. With its cutting-edge research programs and commitment to collaboration and patient advocacy, Tiburio has the potential to make a significant impact on the lives of millions of people around the world who are affected by these devastating conditions.
tiburio.com
